ALERT: We have made the Texas Children’s Health Plan website even easier to use! Click here to learn more.
ALERTA: ¡Ahora el sitio web de Texas Children’s Health Plan es aún más sencillo de usar! Haz clic aquí para más información.
Prior Authorization Criteria Update for Aduhelm Begins July 1
Date: June 15, 2022Attention: All ProvidersSubject: Prior Authorization Criteria Update for Aduhelm Begins July 1Effective Date: July 1, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that the Health and Human Services Commission (HHSC) will update prior authorization criteria for Aduhelm (J0172) in response to recent revisions to the FDA label, and a CMS National Coverage Determination published on April 7, 2022. HHSC will include this update in the July 2022 Texas Medicaid Provider Procedures Manual (TMPPM).
How this impacts providers: Recent evidence suggests that most asymptomatic amyloid-related imaging abnormalities (ARIA) occur during the titration phase of Aduhelm, thus enhanced clinical vigilance is recommended. Beginning July 1, 2022, HHSC will add the following criteria for initial requests:
- The prescriber attestation to obtain a brain magnetic resonance imaging (MRI) prior to the 5th, 7th, 9th, and 12th infusion to check for ARIA.
- Documentation of a brain MRI prior to the 5th, 7th, 9th and 12th infusion to check for ARIA.